Paras Pharmaceuticals Ltd. v. Ranbaxy Laboratories Ltd.

In the fiercely competitive world of over-the-counter products, brands constantly jockey for consumer attention. But what happens when a competitor's advertisement crosses the line from clever marketing into outright disparagement? The 2008 showdown between Paras Pharmaceuticals and Ranbaxy Laboratories offers a masterclass in how trademark law protects brands not just from direct copying, but from the silent, visual attacks designed to undermine them. This case is a wake-up call for every founder who thinks that simply avoiding a competitor's name is enough to stay safe.

Paras Pharmaceuticals Ltd., the maker of the popular pain reliever MOOV, found itself at the receiving end of a marketing campaign it never signed up for. The target of its frustration was Ranbaxy Laboratories Ltd., which was promoting its own pain reliever, VOLINI. Paras alleged that Ranbaxy had launched a series of negative advertisements and TV commercials specifically designed to belittle MOOV and position VOLINI as the superior choice. The crux of Paras's complaint was not that Ranbaxy had used the MOOV name, but rather that Ranbaxy's commercial depicted a box strikingly similar to MOOV's packaging—mirroring its artistic work and color scheme. The implication was unmistakable to viewers: MOOV was being portrayed as the inferior, outdated product.

Paras Pharmaceuticals argued that Ranbaxy's commercial amounted to trademark infringement and disparagement. By replicating the distinctive visual elements of MOOV's trade dress—the artwork and color combination that consumers had come to associate with the brand—Ranbaxy was effectively riding on Paras's goodwill while simultaneously tarnishing it. The visual mimicry, Paras contended, was designed to mislead the average consumer into drawing a direct comparison, subtly suggesting that MOOV was subpar. Ranbaxy, on the other hand, pushed back against the allegations, defending its advertising strategy as legitimate competitive marketing rather than infringement. The legal friction centered on a critical question: can a brand be attacked through imitation and innuendo, even when its name is never spoken?

The Gujarat High Court came down firmly on the side of Paras Pharmaceuticals. The court found that Ranbaxy's commercial had indeed depicted a box identical in artistic work and color scheme to MOOV, and that this visual replication was no accident—it was a calculated move to disparage a competitor's product while misleading consumers. The court allowed Paras's appeal and issued a clear directive: Ranbaxy was ordered to change its packaging colors and to cease using the artwork that belonged to Paras. The ruling sent a powerful message that trademark infringement is not limited to direct copying of a mark; it extends to disparagement, denigration, and the use of similar trade dress that confuses or misleads the average consumer.

For founders and brand builders, this case is a critical reminder: your intellectual property is not just your logo or your name—it is the entire visual identity your customers recognize. If you are building a brand, invest in protecting your